Grace Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	16.98	22.13	23.01	27.88	30.34
Short-Term Investments	-	-	-	0.02	13.32
Cash & Short-Term Investments	16.98	22.13	23.01	27.89	43.66
Cash Growth	-23.30%	-3.79%	-17.52%	-36.12%	-28.11%
Accounts Receivable	0.02	0.13	0.72	0.8	0.55
Other Current Assets	0.38	0.45	0.28	0.6	1.07
Total Current Assets	17.38	22.71	24.01	29.29	45.28
Net Property, Plant & Equipment	0.01	0.02	0.02	0.57	0.57
Other Intangible Assets	41.13	41.13	41.13	41.13	69.81
Goodwill	8.14	8.14	8.14	8.14	12.96
Total Assets	66.65	71.99	73.3	79.12	128.62
Accounts Payable	2.15	1.93	1.68	3.34	3.16
Current Portion of Leases	-	-	-	0.08	0.1
Total Current Liabilities	2.15	1.93	1.68	3.41	3.26
Long-Term Leases	-	-	-	0.41	0.19
Other Long-Term Liabilities	0.61	3.45	9.87	7.35	16.9
Total Long-Term Liabilities	0.61	3.45	9.87	7.76	17.09
Total Liabilities	2.76	5.38	11.56	11.17	20.35
Common Stock	0	0	261.04	258.29	257.99
Additional Paid-in Capital	298.41	293.33	17.86	13.97	12.15
Accumulated Other Comprehensive Income	-6.04	-6.04	-6.04	-6.04	-6.04
Retained Earnings	-228.48	-220.69	-211.12	-198.27	-155.84
Shareholders' Equity	63.9	66.61	61.74	67.96	108.27
Total Liabilities & Equity	66.65	71.99	73.3	79.12	128.62
Total Debt	0	0	0	0.49	0.3
Net Cash (Debt)	16.98	22.13	23.01	27.41	43.37
Net Cash Growth	-23.30%	-3.79%	-16.05%	-36.80%	-28.49%
Net Cash Per Share	1.03	1.83	2.41	3.69	7.06
Book Value	63.9	66.61	61.74	67.96	108.27
Book Value Per Share	3.87	5.51	6.48	9.14	17.63
Tangible Book Value	14.63	17.34	12.48	18.69	25.5
Tangible Book Value Per Share	0.89	1.43	1.31	2.51	4.15

SEC Filings: 10-K · 10-Q